Key result
Metafor sirolimus-eluting stent yields low ~1% 12-month major cardiovascular events rate with zero stent thrombosis in CAD.
Why the study?
The study was designed to evaluate the safety and performance of Metafor SES in real-world patients with coronary artery disease.
Observational (n=141)
No
The biodegradable polymer-coated sirolimus-eluting stent demonstrated favorable safety and performance with a low 1.42% rate of MACE and 0% stent thrombosis at 12 months in a real-world CAD population.
Answers are grounded in this paper and cite their sources.
Should not yet change practice; hypothesis-generating for Metafor SES safety in real-world CAD.
This study was designed to evaluate the safety and performance of Metafor™ SES in real-world patients with coronary artery disease. This was retrospective, single-centre, post-marketing, observational study. The primary endpoint was the occurrence of major adverse cardiac event (MACE). A total of 141 patients (187 lesions) were treated with the study device. The average stent length and diameter was 24.75 ± 9.50 mm and 2.93 ± 0.38 mm, respectively. The cumulative incidence of MACE was 1.42%. No incidence of stent thrombosis was observed at 12-months follow-up. This retrospective study demonstrated favourable safety and performance of Metafor™ SES.
No takes yet. Share an insight, caveat, or question.
Jariwala et al. (2020) conducted an observational in Coronary artery disease (n=141). Metafor sirolimus-eluting stent was evaluated on Major adverse cardiac event (MACE) and stent thrombosis at 12 months. Treatment with the Metafor sirolimus-eluting stent in real-world patients with coronary artery disease resulted in a low 1.42% cumulative incidence of major adverse cardiac events and 0% stent thrombosis at 12 months.
Synapse has enriched 10 related papers. Consider them for comparative context: